Disease Landscape and Forecast Insights

Using national patient-level claims data, this report analyzes physician adherence to the treatment guidelines by exploring the use of key therapies in the newly diagnosed and recently treated…

Non-alcoholic steatohepatitis (NASH) is a common liver disease that can progress to liver fibrosis, cardiovascular disease, and cancer. In the absence of any approved treatments for it, there is a…

Acromegaly is a chronic endocrine disorder characterized by hypersecretion of growth hormone and overproduction of insulin-like growth factor-1. Nearly all cases of acromegaly are caused by an…

Four novel prescription weight-loss agents have launched in the United States since 2012: Vivus’s Qsymia (phentermine/topiramate ER), Arena Pharmaceuticals/Eisai’s Belviq (lorcaserin),…

Mutations in the gene coding for C1-inhibitor (C1-INH) protein result in hereditary angioedema (HAE), whereby insufficient levels of C1-INH or abnormal forms of the protein ultimately result in…

The United States accounts for the single largest proportion of the global medical device market, representing approximately 40% of the estimated $400 billion (USD) global market in 2014. Its large…

Nephrologists and endocrinologists in Europe have had the opportunity to use biosimilar erythropoiesis-stimulating agents (ESAs) and human growth hormone (hGH), respectively, for several years, but…

Over the next ten years, more than 15 million men worldwide Despite the tremendous potential of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, limited market access will…

How Are Payer Strategies and Prescriber Preferences Shaping the Non-Insulin Treatment Algorithm? Although a high opportunity market, the therapeutic space for type 2 diabetes (T2D) is set to…

A Survey of Primary Care Physicians, Endocrinologists, and Managed Care Organization Pharmacy and Medical Directors Type 2 diabetes is a complex metabolic disorder characterized by a declining…

A Survey of Noninterventional Cardiologists, Endocrinologists, and Managed Care Organization Pharmacy and Medical Directors The primary goal of therapy for individuals with dyslipidemia is to…

How Are Payer Policies and Physician Preferences Shaping the Prescribing Landscape? The European oral anticoagulation market has undergone a dramatic expansion in the treatment armamentarium in…